Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05197881 · ClinicalTrials.gov registry record · NA
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
A NA study of Cervical Cancer by FIGO Stage 2018, sponsored by Varian, a Siemens Healthineers Company.
- Recruiting
- Registry status
- NA
- Development phase
- 125
- Enrollment target
- 5
- Study locations
NCT05197881: Recruiting NA study of Cervical Cancer by FIGO Stage 2018, sponsored by Varian, a Siemens Healthineers Company.
NCT05197881 is a NA study of Cervical Cancer by FIGO Stage 2018 that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 125 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05197881, a NA study of Cervical Cancer by FIGO Stage 2018, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 125 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Primary Outcome
GI toxicity as reported by the patient using the gastrointestinal section of the NCI-PRO questionnaire
Conditions Studied
Interventions
- DEVICE Varian Ethos Adaptive Radiation Therapy
Study Locations (5)
Alabama
- University of Alabama Birmingham - Burmingham
Arkansas
- University of Arkansas Medical Sciences - Little Rock
California
- Moores Cancer Center at UC San Diego Health - La Jolla
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2030-09 |
| Phase | NA |
What NCT05197881 shows while recruiting
NCT05197881 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Cervical Cancer by FIGO Stage 2018 appearing as the primary indexed condition, and to 1 intervention - of which Varian Ethos Adaptive Radiation Therapy is the first listed.
NCT05197881 lists 5 locations in 5 states (Alabama, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT05197881 about?
NCT05197881 is a clinical study titled "Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix". This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modul...
What is the current status of trial NCT05197881?
This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2022-05-03. Estimated completion is 2030-09.
What conditions does trial NCT05197881 study?
This clinical trial studies the following conditions: Cervical Cancer by FIGO Stage 2018.
What interventions are being tested in trial NCT05197881?
The interventions under investigation include: Varian Ethos Adaptive Radiation Therapy (DEVICE).
Who is sponsoring clinical trial NCT05197881?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05197881 being conducted?
This trial has 5 study locations across Alabama, Arkansas, California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05197881's enrollment target sits among peer trials
125 753rd of 2000 higher than 1,243 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI